BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia

BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the cornerstone of treatment in chronic myeloid leukemia. Although there are now four TKIs approved for use in the front-line setting, acquired TKI resistance via secondary kinase domain mutations remains a problem for patients. K706 is a novel BCR-ABL1...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Exp Hematol
Autori principali: Antelope, Orlando, Vellore, Nadeem, Pomicter, Anthony D., Patel, Ami B., van Scoyk, Alexandria, Clair, Phillip M., Deininger, Michael, O’Hare, Thomas
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6803074/
https://ncbi.nlm.nih.gov/pubmed/31493432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.exphem.2019.08.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi